Back to Journals » OncoTargets and Therapy » Volume 7

Original Research

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia

       
Total article views   HTML views PDF downloads Totals
13,597 Dovepress* 12,705+ 1,536 14,241
PubMed Central* 892 405 1,297
Totals 13,597 1,941 15,538
*Since 26 September 2014
+Since July 2016

View citations on PubMed Central and Google Scholar